ASSURE Wearable ECG

The ASSURE Wearable ECG is designed for continuous cardiac and activity monitoring in adult patients transitioning from ASSURE WCD therapy, utilizing a familiar garment and established algorithms to capture ECG events and physiological data for clinician review. Its methodology involves ambulatory ECG recording, patient-initiated event marking, and automated detection of heart rate irregularities, with data transmitted wirelessly for non-diagnostic assessment to inform ongoing patient management.

The ASSURE Wearable ECG is a prescription-based, reusable ambulatory system designed for adult patients who were previously prescribed the ASSURE Wearable Cardioverter Defibrillator (WCD) and may exhibit transient cardiac symptoms or be asymptomatic. Its primary purpose is to continuously monitor heart rate information and record ECG data, utilizing the same five-electrode SensorFit™ Garment previously worn with the WCD. The system automatically stores event data for low and high heart rates, as well as patient-triggered events, to aid medical professionals in monitoring clinical conditions, events, and trends during the patient's normal daily activities in various settings. It is explicitly contraindicated for patients with active implantable pacemakers or defibrillators. The ASSURE Wearable ECG system employs the same algorithm detection and episode reporting software marketed in the ASSURE WCD for identifying tachycardia and bradycardia. Beyond ECG, it uses a 3-axis accelerometer to monitor non-ECG patient activity, including steps and wear time. The system components include a Monitor Cable Assembly housing the electronics and communication modules, a Hub, an Alert Button for user input and alerts (audio, visual, haptic), a rechargeable Lithium-Ion Battery Pack, the SensorFit™ Garment, and a charger. Data, including ECG waveforms and identified events, is transferred via Bluetooth to a mobile data client and then to a secure server for clinician review; however, these reports do not provide diagnostic interpretations and are intended to assist prescribers in diagnosis, prognosis, and care planning for patients transitioning from WCD use. The device itself has no user-programmable features and can be worn for up to 30 days.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the system differentiate between true cardiac events and artifacts, especially given its use of the same garment as the WCD which might have different noise profiles in a less acute patient population?; What is the typical data yield and clinical utility of the accelerometer-derived activity data (steps, wear time) in conjunction with ECG event data for this specific patient population transitioning from WCD?; Given that the device uses algorithms from the ASSURE WCD, what adjustments, if any, were made to the sensitivity or specificity of these algorithms for a monitoring (non-therapeutic) context with potentially lower-risk patients?; What are the data security and privacy measures implemented for the transmission of patient data from the device via Bluetooth to a mobile client and then to the Kestra Secure Server?; How does the 'non-diagnostic' nature of the ECG reports influence the clinical workflow and decision-making process for physicians using this device for follow-up care post-WCD?